In the meantime, EMA has approved several MTB-recommended therapies in the respective genomic contexts, such as pembrolizumab for microsatellite instable [27] or pemigatinib for FGFR2 fusion-positive CCA [28]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.